Key Points
- On January 5, insider David Malcom Rodman sold 192,715 shares at an average price of $35.02 for a total of $6,748,879.30, cutting his stake by 75.72% to 61,804 shares.
- Mineralys trades around $35.71 with a market cap of $2.83B and a 1‑year range of $8.24–$47.65; analysts are mostly positive with an average target of $47.43 (six Buys, one Hold, one Sell).
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 70,037 shares of the business's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $35.87, for a total transaction of $2,512,227.19. Following the completion of the transaction, the insider directly owned 69,188 shares of the company's stock, valued at approximately $2,481,773.56. This represents a 50.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
David Malcom Rodman also recently made the following trade(s):
- On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $35.02, for a total transaction of $6,748,879.30.
- On Wednesday, October 15th, David Malcom Rodman sold 10,369 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $43.01, for a total transaction of $445,970.69.
Mineralys Therapeutics Trading Up 0.1%
MLYS opened at $35.71 on Wednesday. The stock has a market capitalization of $2.83 billion, a P/E ratio of -12.11 and a beta of 0.49. Mineralys Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $47.65. The firm's fifty day simple moving average is $39.41 and its 200 day simple moving average is $30.20.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its earnings results on Monday, November 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.14. On average, equities research analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.
Analyst Ratings Changes
Several brokerages recently issued reports on MLYS. Stifel Nicolaus lifted their price target on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a report on Friday, December 19th. Wells Fargo & Company boosted their target price on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the company an "overweight" rating in a report on Tuesday, November 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research note on Wednesday, October 8th. The Goldman Sachs Group boosted their price objective on Mineralys Therapeutics from $32.00 to $52.00 and gave the company a "buy" rating in a report on Tuesday, September 9th. Finally, HC Wainwright boosted their price objective on Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a "buy" rating in a report on Wednesday, November 12th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $47.43.
Check Out Our Latest Research Report on Mineralys Therapeutics
Hedge Funds Weigh In On Mineralys Therapeutics
Institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its position in Mineralys Therapeutics by 51.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company's stock valued at $34,000 after purchasing an additional 850 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Mineralys Therapeutics by 198.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company's stock valued at $40,000 after buying an additional 676 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Mineralys Therapeutics by 42.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company's stock valued at $54,000 after purchasing an additional 1,197 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Mineralys Therapeutics in the 2nd quarter worth about $91,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of Mineralys Therapeutics by 14,091.3% during the third quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company's stock valued at $124,000 after buying an additional 3,241 shares during the last quarter. 84.46% of the stock is currently owned by institutional investors.
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
